Skip to main content
SpringerLink
Log in

Hémopathies malignes rares de l’adulte

  • Chapter
Tumeurs malignes rares

Résumé

Le chapitre consacré à la description des hémopathies malignes rares de l’adulte a été un peu artificiellement subdivisé en deux catégories (les hémopathies lymphoïdes d’un côté et les hémopathies myéloïdes de l’autre), pour plus de clarté. Comme dans toutes tumeurs rares, les données d’incidence et de survie spontanée ou sous traitement sont trés parcellaires et souvent méconnues. Malgré leur caractére orphelin, certaines hémopathies malignes rares ont bénéficié de l’apport récent de nouvelles thérapeutiques qui ont transformé le pronostic et la survie des patients traités.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Lazaro E, Caubet O, Menard, et al. (2007) Leucémies à grands lymphocytes granuleux. Press Med, 36: 1694–1700

    Article  Google Scholar 

  2. Sokol L, Loughran TP (2006) Large Granular Lymphocyte Leukemia. Oncologist 11: 263–73

    Article  CAS  PubMed  Google Scholar 

  3. Dungarwalla M, Matutes E, Dearden CE (2008) Prolymphocytic leukaemia of B-and T-cell subtype: a state-of-the-art paper. Eur J Haematol 80: 469–76

    Article  CAS  PubMed  Google Scholar 

  4. Allsup DJ, Cawley JC (2004) Diagnosis, biology and treatment of hairy-cell leukaemia. Clin Exp Med 4: 132–8

    Article  CAS  PubMed  Google Scholar 

  5. Al-Saleem T, Al-Mondhiry H (2005) Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplams. Blood 105: 2274–80

    Article  CAS  PubMed  Google Scholar 

  6. Dupriez B, Morel P, Demory JL, et al. (1996) Prognostic factors in agnogenic myeloid metaplasia: A report on 195 cases with a new scoring system. Blood 88: 1013–8

    CAS  PubMed  Google Scholar 

  7. Campbell PJ, Griesshammer M, Döhner K, et al. (2006) V617F mutation in JAK 2 is associated with poorer survival in idiopathic myelofibrosis. Blood 107: 2098–100

    Article  CAS  PubMed  Google Scholar 

  8. Barosi G, Bergamaschi G, Marchetti M, et al. (2007) JAK2V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 110: 4030–6

    Article  CAS  PubMed  Google Scholar 

  9. Rondolli D, Barosi G, Bacigalupo A, et al. (2005) Allogeneic stem-cell transplantation with reduced-intensity conditioning in intermediate-or high-risk patients with myelofibrosis with myeloid metaplasia. Blood 105: 4115–9

    Article  Google Scholar 

  10. Pardanani A, Gotlib J, Jamieson C, et al. (2008) A phase I study of TG101348, an orally bioavailable JAK2-selective inhibitor, in patients with myelofibrosis. Blood 112 (suppl. 1) 43, abstract 97

    Google Scholar 

  11. Reilly JT (2002) Chronic neutrophilic leukaemia: A distinct clinical entity? Br J Haematol 116: 10–8

    Article  PubMed  Google Scholar 

  12. Harris NL, Jaffe ES, Diebold J, et al. (1997) World health organisation classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the clinical advisory committee meeting-Airlie house, Virginia, November 1997. J Clin Oncol 17: 3835–49

    Google Scholar 

  13. Reilly JT (2008) Pathogenetic insight and prognostic information from standard and molecular cytogenetic studies in the BCR-ABL negative myeloproliferative neoplasms (MPNs). Leukemia 22: 1818–27

    Article  CAS  PubMed  Google Scholar 

  14. Rothenberg ME, Klion AD, Roufosse FE, et al. (2008) Treatment of patients with hypereosinophilic syndrome with mepolizumab. N Engl J med 358: 1215–28

    Article  CAS  PubMed  Google Scholar 

  15. Lefebvre C, Bletry O, Degoulet P, et al. (1989) Prognostic factors of hypereosinophilic syndrorme. Study of 40 cases. Ann Med Interne 140: 253–7

    CAS  Google Scholar 

  16. Apperley JF, Gardembas M, Melo JV, et al. (2002) Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 347: 481–7

    Article  CAS  PubMed  Google Scholar 

  17. Cools J, DeAngelo DJ, Gotlib J, et al. (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348: 1201–14

    Article  CAS  PubMed  Google Scholar 

  18. Wilkins HJ, Crane MM, Copeland K, et al. (2005) Hypereosinophilic syndrome: An update. Am J Hematol 80: 148–157

    Article  PubMed  Google Scholar 

  19. Gotlib J, Cools J, Malone JM, et al. (2004) The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukaemia: Implications for diagnosis, classification and management. Blood 103: 2879–91

    Article  CAS  PubMed  Google Scholar 

  20. Valent P, Akin C, Escribano L, et al. (2007) Standards and standardisation in mastocytosis: Consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 37: 435–53

    Article  CAS  PubMed  Google Scholar 

  21. Metcalfe DD (2008) Mast cells and mastocytosis. Blood 112: 946–56

    Article  CAS  PubMed  Google Scholar 

  22. Metcalfe DD, Soter NA (2000) Mast cell disorders. Hematology/Oncology clinics of north America, 14, no 3. WB Sanders company Eds, Phildelphia, PA, USA

    Google Scholar 

  23. Germing U, Strupp C, Knipp S, et al. (2007) Chronic myelomonocytic leukemia in the light of the WHO proposals. Haematologica 92: 974–7

    Article  PubMed  Google Scholar 

  24. Hirsch-Ginsberg C, LeMaistre AC, Kantarjian H, et al. (1900) RAS mutations are rare events in Philadelphia chromosome negative/bcr gene rearrangement-negative chronic myelogenous leukaemia, but are prevalent in chronic myelomonocytic leukaemia. Blood 76: 1214–9

    Google Scholar 

  25. Orazi A, Germing U (2008) The myelodysplastic/myeloproliferative neoplasms: Myeloproliferative diseases with dysplastic features. Leukemia 22: 1388–91

    Article  Google Scholar 

  26. Griffiths EA, Gore SD (2008) DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Semin Hematol 45: 23–30

    Article  CAS  PubMed  Google Scholar 

  27. Fenaux P, Kelaidi C (2006) Treatment of the 5q-syndrome. Hematology Am Soc Hematol Educ Program 192–8

    Google Scholar 

  28. List A, Kurtin S, Roe DJ et al. (2005) Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352: 549–57

    Article  CAS  PubMed  Google Scholar 

  29. Dominigo-Claros A, Larriba I, Rozman M, et al. (2002) Acute erythroid neoplastic proliferations. A biological study based on 62 patients. Haematologica 87: 148–53

    Google Scholar 

  30. Tallman MS, Neuberg D, Bennett JM, et al. (2000) Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience. Blood 96: 2405–11

    CAS  PubMed  Google Scholar 

  31. Parker C, Omine M, Richards S. et al. (2005) Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 106: 3699–709

    Article  CAS  PubMed  Google Scholar 

  32. Parker CJ, Bessler M, Hiken J, et al. (2008) Paroxysmal nocturnal hemoglobinuria. Hematology Am Soc Hematol Educ Prog 92–123

    Google Scholar 

  33. Owaida TM, Al Beihany A, Iqbal MA, et al. (2006) Cytogenetics, molecular and ultrastructural characteristics of biphenotypic acute leukemia identified by the EGIL scoring system. Leukemia 20: 620–6

    Article  Google Scholar 

  34. Aribi A, Bueso-Ramos C, Estey A. et al. (2007) Biphenotypic acute leukaemia: a case series. Br J Haematol 138: 213–6

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d’hématologie clinique, Hôpital Edouard-Herriot, 5, place d’Arsonval, 69437, Lyon Cedex 03

    Emmanuelle Nicolas-Virelizier, Matthias Jacquet-Lagrèze & Franck Emmanuel Nicolini

Authors
  1. Emmanuelle Nicolas-Virelizier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthias Jacquet-Lagrèze
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Franck Emmanuel Nicolini
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag France, Paris

About this chapter

Cite this chapter

Nicolas-Virelizier, E., Jacquet-Lagrèze, M., Nicolini, F.E. (2010). Hémopathies malignes rares de l’adulte. In: Tumeurs malignes rares. Springer, Paris. https://doi.org/10.1007/978-2-287-72070-3_50

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-72070-3_50

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-72069-7

  • Online ISBN: 978-2-287-72070-3

Publish with us

Policies and ethics

Search

Navigation